XXXX treatment for @entity4018 : Efficacy and tolerability in routine practice.

@entity1 @entity137 @entity417 @entity882 @entity26223 @entity4018 @entity381
UNASSIGNED: @entity26223 has been shown in two randomized clinical trials to be effective in alleviating systemic symptoms and reducing spleen size in @entity1 with @entity4018 ( @entity4018 ). We retrospectively evaluated efficacy and tolerability of @entity26223 in a cohort of unselected @entity4018 @entity1 treated in routine clinical practice. One hundred and two @entity1 who began @entity26223 therapy were identified in 13 participating centers. Ninety three of the @entity1 receiving @entity26223 for at least 3 months were evaluated for treatment efficacy and @entity137 . Median age at @entity26223 initiation was 67 years. Indications for treatment were constitutional symptoms (15%), symptomatic @entity381 (6%) or both (76%). Two @entity1 received @entity26223 for other indications. The median initial @entity26223 dose was 30mg/day. Median duration of therapy was 11 months. Eighty two @entity1 (88.2%) responded to therapy, 76 (84.4%) @entity1 had improvement in constitutional symptoms and 60 @entity1 (70.6%) had reduction in spleen length. While on @entity26223 , 30% of @entity1 had grade 3-4 @entity417 and 12.9% of @entity1 had grade 3-4 @entity882 . Thirteen @entity1 (14%) discontinued therapy. This analysis of a cohort of @entity4018 @entity1 treated with @entity26223 in routine clinical practice demonstrates the efficacy and tolerability of this drug outside of a highly monitored clinical trial setting.
